Bone marrow transplantation for patients with acquired severe aplastic anemia using cyclophosphamide and antithymocyte globulin: The experience from a single center

Hematology Journal

Volumn 4, Issue 3, 2003, Pages 208-213

  Abdelkefi, Abderrahman ^a   Othman, Tarek Ben ^a   Ladeb, Saloua ^a   Torjman, Lamia ^a   Hsaïri, Mohamed ^b   Abdeladhim, Abdeladhim Ben ^a  

^a CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE   (Tunisia)

Author keywords

Allogeneic marrow transplantation; Aplastic anemia; Cyclophosphamide and antithymocyte globulin conditioning

Indexed keywords

ACICLOVIR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; METHOTREXATE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CANDIDIASIS; CHILD; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DONOR; FEMALE; FOLLOW UP; GENOTYPE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HERPES; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MONOZYGOTIC TWINS; PROGNOSIS; PROPHYLAXIS; SIBLING; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; MALE; RETROSPECTIVE STUDIES; SIBLINGS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, ISOGENEIC; TREATMENT OUTCOME;

EID: 0037715406     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200246     Document Type: Article

References (29)

1. Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy. The European Group for Blood and Marrow Transplantation Experience. Semin Hematol 2000; 37: 69-80.
2. Storb R, Blume KG, O'Donnell MR, Chauncey T, Forman SJ, Deeg HJ et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 2001; 7: 39-44.
3. Stucki A, Leisenring W, Sandmaier BM, Sanders J, Anasetti C, Storb R. Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). Blood 1998; 92: 2742-2749.
4. de Medeiros CR, Bitencourt MA, Medeiros BC, Ioshizumi L, Pasquini R. Second bone marrow transplantation for severe aplastic anemia: analysis of 34 cases. Bone Marrow Transplant 2001; 28: 941-944.
5. Locatelli F, Bruno B, Zecca M, Van-Lint MT, Mc Cann SR, Arcese W et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 2000; 96: 1690-1697.
6. Storb R, Deeg HJ, Farawell V, Doney K, Appelbaum FR, Beatty P et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 63: 119-125.
7. Passweg JR, Socié G, Hinterberger W, Bacigalupo A, Biggs JC, Camitta BM et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood 1997; 90: 858-864.
8. Wagner JL, Storb R. Allogeneic transplantation for aplastic anemia. In: Forman SJ, Blume KG, Thomas ED (eds). Hematopoietic Cell Transplantation, 2nd edn. Black-well Science: Oxford, 1999, pp 791-806.
9. Socié G, Henry-Amar M, Cosset JM, Devergie A, Girinsky T, Gluckman E. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood 1991; 78: 277-279.
10. Storb R, Weiden PL, Sullivan KM, Appelbaum FR, Beatty P, Buckner CD et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood 1987; 70: 116-121.
11. Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941-949.
12. Camitta BM, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC, Gale RP et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood 1976; 48: 63-70.
13. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-2061.
14. Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989; 73: 606-613.
15. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow HLA-matched sibling donors. Transplantation 1974; 18: 295-301.
16. Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA et al. Risk factors for graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459-2464.
17. Bryant E, Martin PJ. Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation. In: Forman SJ, Blume KG, Thomas ED (eds), Hematopoietic Cell Transplantation. 2nd edn. Black-well Science: Oxford, 1999, pp 197-206.
18. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
19. McCann SR, Bacigalupo A, Gluckman E, Hinterberger W, Hows J, Ljungman P et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant 1994; 13: 233-237.
20. Doney K, Leisenring W, Storb R, Appelbaum FR. for the Seattle Bone Marrow Transplant Team. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Ann Intern Med 1997; 126: 107-115.
21. Horowitz MH. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol 2000; 37: 30-42.
22. Storb R, Weiden PL, Deeg HJ, Graham TC, Atkinson K, Slichter SJ et al. Rejection of marrow from DLA-identical canine littermates given transfusions before grafting: antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells. Blood 1979; 54: 477-484.
23. Bean MA, Storb R, Graham T, Raff R, Sale GE, Schuening F et al. Prevention of transfusion-induced sensitization to minor histocompatibility antigens on DLA-identical canine marrow grafts by gamma irradiation of marrow donor blood. Transplantation 1991; 52: 956-960.
24. Bean MA, Graham T, Appelbaum FR, Deeg HJ, Schuening F, Sale GE et al. Gamma-irradiation of pretransplant blood transfusions from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leucocyte antigen-identical canine marrow grafts. Transplantation 1994; 57: 423-426.
25. Niederwieser D, Pepe M, Storb R, Loughran Jr TP, Longton G for the Seattle Marrow Transplant Team. Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anemia. Br J Haematol 1988; 69: 23-28.
26. Bunin N, Leahey A, Kamani N, August C. Bone marrow transplantation in pediatric patients with severe aplastic anemia: cyclophosphamide and anti-thymocyte globulin conditioning followed by recombinant human granulocyte-macrophage colony stimulating factor. J Pediatr Hematol Oncol 1996; 18: 68-71.
27. Horstmann M, Stockschlader M, Kruger W, Hoffknecht M, Betker R, Kabisch H et al. Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: preliminary results. Ann Hematol 1995; 71: 77-81.
28. Azuma E, Kojima S, Kato K, Matsuyama T, Yamada Y, Kondo N et al. Conditioning with cyclophosphamide/antithymocyte globulin for allogeneic bone marrow transplantation from HLA-matched siblings in children with severe aplastic anemia. Bone Marrow Transplant 1997; 19: 1085-1087.
29. Kojima S, Kobayashi R, Yabe H, Nishimura S, Yagi K, Yoshihara T et al. High incidence of graft rejection in children with severe aplastic anemia preconditioned with cyclophosphamide and antithymocyte globulin regimen. Blood 2001; 98: 376b (abstract 5284).